Skip to main content
OpenTrials
Completed

NCT Number: NCT04311177

Losartan for Patients With COVID-19 Not Requiring Hospitalization

This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Corona Virus Infection Acute Respiratory Distress Syndrome COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiration Disorders Respiratory Distress Syndrome Respiratory Tract Diseases Respiratory Tract Infections SARS-CoV Infection Severe Acute Respiratory Syndrome Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hennepin County Medical Center, Minneapolis, Minnesota, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Positive laboratory test for COVID-19 based on local laboratory standard
  • Age greater than or equal to 18 years of age
  • One of the following: Upper respiratory symptoms (cough, rhinorrhea) or fever (>101.5) or loss of taste / smell

Exclusion criteria

  • Randomization > 72 hours of meeting inclusion criteria
  • Randomization > 7 days of symptom onset
  • Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB)
  • Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to angioedema
  • Pregnant or breastfeeding women
  • Females able to have children not currently taking a protocol allowed version of contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate/Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives with verbalized commitment to taking daily throughout the study, condom use or abstinence during the study. All participants of child bearing potential enrolled in this fashion will be informed of the teratogenic risks.
  • Patient reported history or electronic medical record history of kidney disease, defined as:
  • Any history of dialysis
  • History of chronic kidney disease stage IV
  • Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 (must be have been measured within 1 month of enrollment)
  • Other kidney disease that in the opinion of the investigator, would affect losartan clearance
  • Patient reported dehydration and significantly decreased urine output in the past 72 hours
  • Most recent systolic blood pressure prior to enrollment <110 mmHg
  • Patient reported history or electronic medical record history of severe liver disease, defined as:
  • Cirrhosis
  • History of hepatitis B or C
  • Other liver disease that in the opinion of the investigator, would affect losartan clearance
  • Documented AST or ALT > 3 times the upper limit of normal within 3 months of randomization (if available in electronic medical record)
  • Potassium >5.0 mmol/L (must have been measured within 1 month) of enrollment
  • Concurrent treatment with aliskiren
  • Inability to obtain informed consent
  • Enrollment in another blinded randomized clinical trial for COVID

Treatment and study plan

Losartan

Drug

Losartan; 25 mg daily; oral administration

Other names: Cozaar

Placebo

Other

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

Primary outcomes

  1. Percentage of Participants Admitted to the Hospital

    Time frame: 15 days

    Outcome reported as the percentage of participants per arm admitted to inpatient hospital care due to COVID-19-related disease within 15 days of randomization.

    Currently, there is a pre-planned pooled analysis with a national trial network under development.

Secondary outcomes

  1. Change in PROMIS Dyspnea Scale

    Time frame: 10 days

    The PROMIS dyspnea scale consists of 4 subscales. 3 (1. general shortness of breath, 2. intensity, and 3. Frequency) are scored from 0 (no symptoms) to 10 (most severe). The 4th subscale is scored from 0-4 in response to the question "I've been short of breath" with 0 representing none and 4 the most severe, for a total range of 0-34. Results are difference between enrollment and day 10. There are no units.

  2. Change in SF-12 Physical Composite Score

    Time frame: 10 days

    The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Physical score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The 33-item Severity bank assesses the severity of difficulty breathing during various specific activities (the same 33 activities assessed in Dyspnea Functional Limitations). Each activity is rated in terms of degree of dyspnea (0 = no shortness of breath, 1 = mildly short of breath, 2 = moderately short of breath, 3 = severely short of breath) while engaging in the activity over the past 7 days. Total scores range from 0 to 99 with higher scores reflecting greater levels of dyspnea during daily activity.

  3. Change in SF-12 Mental Composite Score

    Time frame: 10 days

    The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Mental composite score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

  4. Daily Maximum Temperature

    Time frame: 10 days

    Participants will report their maximum daily oral temperature to the study team. Outcome is reported as the mean maximum daily body temperature (in degrees Celsius) over 10 days.

  5. Count of Participants With an Emergency Department or Clinic Presentation

    Time frame: 28 days

    Outcome is reported as the mean number of emergency department and clinic presentations combined per participant in each arm.

  6. Disease Severity Rating Day 15

    Time frame: 15 days

    Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.

  7. Change in Viral Load by Nasopharyngeal Swab at Day 9

    Time frame: 9 days

    Viral load is measured as number of viral genetic copies per mL.

  8. Change in Viral Load by Nasopharyngeal Swab at Day 15

    Time frame: 15 days

    Viral load is measured as number of viral genetic copies per mL.

  9. Percentage of Patients Admitted to the Intensive Care Unit Within 15 Days

    Time frame: 15 days

    Outcome reported as the percent of participants in each arm who require ICU admission by day 15 following randomization.

  10. Need for Oxygen Therapy at 15 Days

    Time frame: 15 days

    Outcome reported as the percent of participants in each arm who require oxygen therapy by day 15 following randomization.

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 17, 2020
Registry last updated
May 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.